

Curriculum Vitae for: Kathleen M. Egan, ScD
Date: 1/06/2009

Current Position: Senior Member
Division of Population Sciences
Department of Epidemiology and Genetics
Risk Assessment, Detection & Intervention Program
H. Lee Moffitt Cancer Center & Research Institute
12902 Magnolia Drive
Tampa, FL 33612
(813)-745-6149- phone #
(813)-745-6525- fax #
Kathleen.Egan@moffitt.org

Education:

1979	B.S.	University of Connecticut
1984	M.P.H	Boston University
1996	Sc.D.	Harvard University

Academic Appointments and Employment:

4/1989-6/1991	Research Associate, Department of Ophthalmology, Harvard Medical School
7/1991-6/1997	Instructor, Department of Ophthalmology, Harvard Medical School
7/1996-6/1998	Research Associate, Department of Epidemiology Harvard School of Public Health
7/1997-5/2002	Assistant Professor, Department of Ophthalmology Harvard Medical School
7/1998-5/2002	Assistant Professor, Department of Epidemiology Harvard School of Public Health
6/2002-9/2006	Associate Professor, Department of Medicine Vanderbilt University School of Medicine
1/2003-6/2006	Associate Professor (Adjunct), Department of Epidemiology Harvard School of Public Health
9/2006-present	Professor, Department of Oncologic Sciences (formerly: Interdisciplinary Oncology) Professor, Department of Biostatistics & Epidemiology, University of South Florida
9/2006- present	Senior Member, Risk Detection, Prevention & Intervention Program, Moffitt Cancer Center & Research Institute

Teaching Experience

1. University Courses:

1999	Instructor, <u>Practice of Epidemiology (EPI 205ab)</u> , Harvard School of Public Health, Boston, MA
2001	Instructor, <u>Molecular Epidemiology of Cancer (EPI 250b)</u> , Harvard School of Public Health, Boston, MA
2003-2006	Guest Lecturer, <u>Introduction to Cancer Biology (CB 342)</u> , Vanderbilt University Medical Center School of Medicine, Nashville, TN

2. Teaching and Training Experience:

Graduate training:

1999-2002	Research Advisor, PhD Graduate Student Supervisory Committee for Wenjun Li, PhD, Department of Biostatistics, University of Massachusetts at Amherst.
1999-2001	Research Advisor, PhD Graduate Student Supervisory Committee for Elisabeth Bertone, Department of Epidemiology, Harvard School of Public Health.
2000-2001	Research Advisor, MPH Graduate Student Supervisory Committee for Nicole Leong, Department of Epidemiology, Harvard School of Public Health.
2000-2001	Research Advisor, MPH Graduate Student Supervisory Committee for Jorge Arroyo, MD, Department of Epidemiology, Harvard School of Public Health.
2000-2006	Research Advisor, PhD Graduate Student Supervisory Committee for Laura Mignone, Department of Epidemiology, Harvard School of Public Health.
2000-2001	Research Advisor, PhD Graduate Student Supervisory Committee for James Kaye, MD, Department of Epidemiology, Harvard School of Public Health.
2001-2002	Research Advisor, MPH Graduate Student Supervisory Committee for Jennifer Quinn, MD, Tufts School of Public Health
2005-2007	Research Advisor, PhD program in Human Genetics for Sharon Liang, MD, Department of Cancer Biology, Vanderbilt University.
2005-2007	Research Advisor, MPH Graduate Student Supervisory Committee for Natalie Curcio, MD, Vanderbilt University
2008-	Research Advisor, Directed Research Project for Jennifer Permut-Wey, PhD candidate, University of South Florida, entitled "Family History is a Significant Risk Factor for Pancreatic Cancer: Results from a Systematic Review and Meta-Analysis"
2008-	Research Advisor for Gabriella Anic, PhD candidate, University of South Florida, for project entitled "Tea Consumption and Risk of Breast Cancer"

Faculty Mentoring:

- 2003-present Neereja Peterson, MD, MPH, Assistant Professor, Vanderbilt University Medical Center, Nashville, TN.
- 2003-present Alecia Malin, PhD, Assistant Professor, Meharry Medical College, Nashville, TN.
- 2009-present Michael Yu, MD, Assistant Faculty Member, Moffitt Cancer Center, Tampa, FL.

Honors and Awards

1. American Academy of Ophthalmology Honor Award, 1994.
2. Recognition for Excellence in Teaching: Committee on Educational Policy, Harvard School of Public Health, 2001.

Research Support

Current

External Grants:

Account #: R01 (CA116174) **Kathleen M. Egan, Sc.D – PI**
Dates: 6/1/2007-5/31/2012
Source: NCI
Title: Southeastern Regional Case-Control Study of Adult Glioma
% Effort: 40%
Role in the Study: Principal Investigator
Total Direct Costs: \$ 3,981,218
Total Amount of Award: \$ 6,489,385

PI: **Nagi Kumar, PhD - PI**
Dates: 7/1/2007-6/30/2012
Source: NCI
Title: A Phase II Clinical trial of Polyphenon E in Prostate Cancer
% Effort: 3%
Role in the Study: Co-investigator
Total Direct: \$ 3,860,256
Total Amount of Award: \$ 6,292,217

PI: **Vern Sondak, MD - PI**
Dates: 7/1/2007-6/30/2010
Source: Bankhead-Coley FL Biomedical Research Program
Title: Melanoma PreSpore
% Effort: 15%
Role in the Study: Project Leader
Total Direct: \$ 916,667 (year01)
Total Amount of Award: \$ 990,000 (year01)

Pending

External Grants:

Principal Investigator: **Narod SA - PI**
Dates: 7/1/2007-6/30/2012
Source: Komen for the Cure
Title: Breast Cancer in Blacks: The ASPIRE (Advancing the Study of Progression, Inheritance, Risks and Etiology) Project
% Effort: 10%
Role in the Study: Co-Investigator
Total Direct (requested): \$ 4,077,217 (Moffitt Sub)
Total Award (requested): \$ 5,096,522 (Moffitt Sub)
Date Submitted: December 4, 2008

Account #: R01 (CA136785) **Kathleen M. Egan, Sc.D - PI**
Dates: 12/1/2008-11/30/2013
Source: NCI
Title: Lymphangiogenesis/ Angiogenesis Gene Variants and Melanoma Outcome
% Effort: 25%
Role in the Study: Principal Investigator
Total Direct (requested): \$ 2,320,432
Total Award (requested): \$ 3,807,218
Date Submitted: November 5, 2008

Account #: R01 (CA138606) **Kathleen M. Egan, Sc.D - PI**
Dates: 4/1/2009-3/31/2014
Source: NCI
Title: Vitamin D, Inflammation & Host Phenotypes: The Melanoma 'VIP' Outcomes Consortium
% Effort: 25%
Role in the Study: Principal Investigator
Total Direct (requested): \$ 2,447,320
Total Award (requested): \$ 3,969,259
Date Submitted: June 5, 2008

Account #: R03 (CA139580) **Kathleen M. Egan, Sc.D - PI**
Dates: 4/1/2009-3/31/2011
Source: NCI
Title: Trace Metals and Risk of Adult Glioma: A Pilot Study
% Effort: 5%
Role in the Study: Principal Investigator
Total Direct (requested): \$ 109,365
Total Award (requested): \$ 180,250
Date Submitted: July 21, 2008

Completed

External Grants:

Account #: R01 (CA105197)	Kathleen M. Egan, Sc.D – PI
Dates:	9/1/2004-12/31/2007
Source:	NCI
Title:	Gene Interactions, Estrogen and Risk of Invasive Breast Cancer
% Effort:	40%
Role in the Study:	Principal Investigator
Total Direct Costs:	\$ 1,159,328
Total Amount of Award: \$	\$ 1,616,812
Account #: R03 (CA119751)	Kathleen M. Egan, Sc.D – PI
Dates:	7/1/2006-6/30/2008
Source:	NCI
Title:	Serum Vitamin D and Mortality from Eye Melanoma
% Effort:	5%
Role in the Study:	Principal Investigator
Total Direct Costs:	\$ 121,982
Total Amount of Award:	\$ 175,390
Account #: R01 (CA47305)	Kathleen M. Egan, Sc.D – PI
Dates:	6/01/1996-5/31/2002
Source:	NCI
Title:	Hormones, Lifestyle, and Breast Cancer
Role in the Study:	Principal Investigator
Account #: R01 (CA47305)	Kathleen M. Egan, Sc.D – PI
Dates:	6/01/1996-5/31/2002
Source:	NCI
Title:	Hormones, Lifestyle and Breast Cancer- Supplement
Role in the Study:	Principal Investigator
Account #: R01 (CA67264)	Kathleen M. Egan, Sc.D – PI
Dates:	7/01/1996-6/30/2001
Source:	NCI
Title:	Risk Factors and Biomarkers for in Situ Breast Cancer
Role in the Study:	Principal Investigator
Account #: R01 (CA47305)	Kathleen M. Egan, Sc.D – PI
Dates:	10/01/1998-9/30/2000
Source:	NCI
Title:	Risk Factors and Biomarkers for in Situ Breast Cancer- Supplement
Role in the Study:	Principal Investigator

Relinquished

PI: **Kathleen M. Egan, Sc.D - PI**
Dates: 7/1/2007-6/30/2008
Source: Bankhead-Coley FL Bridge Funding Program
Title: Southeast Region Case-Control Study of Adult Glioma
% Effort: 10%
Role in the Study: Principal Investigator
Total Direct: \$ 250,000
Total Amount of Award: \$ 250,000

Consultations

Account #: U54 (CA091408) **Alecia Malin Fair (Meharry Medical College) – PI**
Dates: 12/18/2006-11/30/2009
Source: NCI
Title: Vitamin D and mammographic breast density in African American women

Account #: K07 (CA122827) **Neeraja Peterson (Vanderbilt University) – PI**
Dates: 7/1/07-6/30/2011
Source: NCI
Title: Matrix metalloproteinase gene polymorphism and breast cancer risk and survival

Service

Harvard School of Public Health

1. Administrative Appointments:

1996-2006: **Faculty Advisor:** Department of Epidemiology Graduate Students.

2. Committees:

1997: **Member,** Student Selection Committee.

Vanderbilt University Medical Center

1. Committees:

2002-2006 **Member,** American Cancer Society – RG Review Committee.
2002-2006 **Member,** Pilot Project Review Panel, Center for Nutritional Research Unit.
2002-2003 **Member,** Planning Committee: Head & Neck Cancer SPORE
2003-2004 **Member,** Advisory Committee: Education and Career Development Plan for Symptom and Behavioral Management Cancer Training Program (R25T)
2003-2006 **Member,** Vanderbilt-Meharry Alliance.

Moffitt Cancer Center & Research Institute

1. Committees:

2007- present **Member,** Scientific Review Committee
2007- present **Member,** Committee on Appointments, Promotion and Tenure
2007- present **Member,** Peer Review Panel: Comprehensive Melanoma Research Center

Professional:

1989-

Ad Hoc Reviewer for peer-reviewed journals:

American Journal of Epidemiology
American Journal of Ophthalmology
Archives of Ophthalmology
BMC Cancer
Breast Cancer Research & Treatment
Cancer Causes & Control
Cancer Epidemiology, Biomarkers & Prevention
Cancer Letters
Cancer Research
Clinical Cancer Research
Clinical Pharmacology and Therapeutics
Eye
Lancet
Melanoma Research
Ophthalmology
Journal of the American Medical Association
Journal of the National Cancer Institute

1997-

Epidemiology Peer Review Panel (ad hoc), Breast Cancer Research Program, USAMRDC

1998-

Epidemiology Peer Review Panels (ad hoc), National Cancer Institute

2004-

American Association for Cancer Research Program Committee

2007-

Associate Editor, Cancer Causes & Control

2008-

Susan G. Komen for the Cure Grants Program Peer Review Panel

2008-

Associate Editor; Cancer Epidemiology Biomarkers and Prevention (CEBP)

Professional Association Memberships

1984-

Association for Research in Vision and Ophthalmology

1984-

Society for Epidemiologic Research

1990-

Society for Clinical Trials

1994-

American Association for Cancer Research

2006-

Society of Neuro-Oncology

Peer-Reviewed Publications

1. Gragoudas E, Seddon J, **Egan KM**, Polivogianis L, Hsieh CC, Goitein M, Verhey L, Munzenrider J, Austin-Seymour M, Urie M, Koehler A. Prognostic factors for metastasis following proton beam irradiation of uveal melanomas. *Ophthalmology* 1986; 93: 675-680.
2. Seddon J, Gragoudas E, Polivogianis L, Hsieh CC, **Egan KM**, Goitein M, Verhey L, Munzenrider J, Austin-Seymour M, Urie M, Koehler A. Visual outcome after proton beam irradiation of uveal melanoma. *Ophthalmology* 1986; 93: 666-674.
3. Seddon JM, Gragoudas ES, Albert DM, Hsieh CC, Polivogianis L, **Egan KM**. Echographic and histologic tumor height measurements in uveal melanoma. *Am J Ophthalmol* 1986; 101: 126-127.
4. Seddon JM, Polivogianis L, Gragoudas ES, Hsieh CC, **Egan KM**. Enucleation vs. cobalt 60 irradiation of melanomas (letter to editor). *Arch Ophthalmol* 1986; 104: 175-176.

5. Ormerod L, **Egan KM**. Spontaneous hyphaema and corneal hemorrhage as complications of microbial keratitis. *Br J Ophthalmol* 1987; 71: 933-937.
6. Gragoudas E, Seddon J, **Egan KM**, Glynn R, Munzenrider J, Austin-Seymour M, Goitein M, Verhey L, Urie M, Koehler A. Long-term results of proton beam irradiated uveal melanomas. *Ophthalmology* 1987; 94: 349-353.
7. Seddon J, Gragoudas E, **Egan KM**, Glynn R, Munzenrider J, Austin-Seymour M, Goitein M, Verhey L, Urie M, Koehler A. Uveal melanomas near the optic disc or fovea: visual results after proton beam irradiation. *Ophthalmology* 1987; 94: 354-361.
8. Gragoudas ES, Seddon JM, **Egan KM**, Glynn RJ, Goitein M, Munzenrider J, Verhey L, Urie M, Koehler A. Metastasis from uveal melanoma after proton beam irradiation. *Ophthalmology* 1988; 95: 992-999.
9. **Egan KM**, Gragoudas E, Seddon J, Glynn R, Munzenrider J, Goitein M, Verhey L, Urie M, Koehler A. The risk of enucleation after proton beam irradiation of uveal melanoma. *Ophthalmology* 1989; 96: 1377-83.
10. Glynn R, Seddon J, Gragoudas E, **Egan KM**, Hart L. Evaluation of tumor regression and other prognostic factors for early and late metastasis after proton beam irradiation of uveal melanoma. *Ophthalmology* 1989; 96:1566-1573.
11. Lischko A, Seddon J, Gragoudas E, **Egan KM**, Glynn R. Evaluation of prior primary malignancy as a determinant for uveal melanoma. *Ophthalmology* 1989; 96:1716-1721.
12. Flotte T, Seddon J, Zhang Y, Glynn R, **Egan KM**, Gragoudas, E. A computerized image analysis method for measuring elastic tissue and solar elastosis. *J Invest Dermatol* 1989; 93: 358-362.
13. Schein OD, Ormerod LD, Barraquer E, Alfonso E, **Egan KM**, Paton BG, Kenyon KR. Microbiology of contact lens-related keratitis. *Cornea* 1989; 8:281-5.
14. **Egan KM**, Gragoudas E, Seddon J, Glynn R, Munzenrider J, Goitein M, Verhey L, Urie M, Koehler A. The risk of enucleation after proton beam irradiation of uveal melanoma [summary]. *Ophthalmol Digest* 1990; 2: 6-7.
15. Seddon JM, Gragoudas ES, **Egan KM**, Glynn RJ, Howard S, Fante RJ, Albert DM. Relative survival rates after alternative therapies for uveal melanoma. *Ophthalmology* 1990; 97:769-777.
16. Smith EV, Kolodny NH, Gragoudas ES, **Egan KM**, Finn S, D'Amico DJ, Seddon JM. An NMR blood test for uveal melanoma? *Invest Ophthalmol Vis Sci* 1990; 31:993-997.
17. Seddon JM, Gragoudas ES, Glynn RJ, **Egan KM**, Albert DM, Blitzer PH. Host factors, ultraviolet radiation and risk of uveal melanoma: A case-control study. *Arch Ophthalmol* 1990; 108:1274-1280.
18. Gragoudas ES, **Egan KM**, Seddon JM, Glynn RJ, Walsh SM, Finn SM, Munzenrider JE, Spar MD. Survival of patients with metastases from uveal melanoma. *Ophthalmology* 1991; 98:383-390.
19. Seddon J, Gragoudas E, **Egan KM**, Polivogianis L, Finn S, Albert D. Standardized data collection and coding in eye disease epidemiology: The uveal melanoma data system. *Ophthalmic Surg* 1991; 22: 127-136.
20. Gragoudas ES, **Egan KM**, Arrigg P, Seddon JM, Glynn RJ. Cataract extraction after proton beam irradiation. *Arch Ophthalmol* 1992; 110:475-79.
21. **Egan KM**, Gragoudas ES, Seddon JM, Walsh SM. Smoking and the risk of early metastases from choroidal melanoma. *Ophthalmology* 1992; 99:537-41.
22. Seddon JM, **Egan KM**, Zhang Y, Gelles EJ, Glynn RJ, Tucker CA, Gragoudas ES. Evaluation of skin microtopography as a measure of ultraviolet exposure. *Invest Ophthalmol Vis Sci* 1992; 33:1903-08.
23. Marcus DM, Mawn LA, **Egan KM**, Albert DM. Nucleolar organizer regions in iris nevi and melanomas. *Am J Ophthalmol* 1992; 114:202-7.

24. Gragoudas ES, **Egan KM**, Seddon JM, Walsh SM, Munzenrider JE. Intraocular recurrence of uveal melanoma after proton beam irradiation. *Ophthalmology* 1992; 99:760-766.
25. Guyer DR, Mukai S, **Egan KM**, Seddon JM, Walsh SM, Gragoudas ES. Radiation maculopathy following proton beam irradiation for choroidal melanoma. *Ophthalmology* 1992; 99:1278-85.
26. Saornil MA, **Egan KM**, Gragoudas ES, Seddon JM, Walsh SM, Albert DM. Histopathology of proton beam irradiated versus enucleated uveal melanomas. *Arch Ophthalmol* 1992; 110:1112-8.
27. Ajani UA, Seddon JM, Hsieh C-C, **Egan KM**, Albert DM, Gragoudas ES. Occupation and risk of uveal melanoma: An exploratory study. *Cancer* 1992; 70:2891-2900.
28. Gragoudas ES, **Egan KM**, Saornil MA, Walsh SM, Albert DM, Seddon JM. The time course of irradiation changes in proton beam treated uveal melanomas. *Ophthalmology* 1993; 100:1555-60.
29. Weinberg DV, **Egan KM**, Seddon JM. The asymmetric distribution of arteriovenous crossings in the normal retina. *Ophthalmology* 1993; 100:31-6.
30. **Egan KM**, Walsh SM, Seddon JM, Gragoudas ES. An evaluation of reproductive factors on the risk of metastases from uveal melanoma. *Ophthalmology* 1993; 100:1160-66.
31. Colditz GA, **Egan KM**, Stampfer MJ. Hormone replacement therapy and risk of breast cancer: results from epidemiologic studies. *Am J Obstet Gynecol* 1993; 168:1473-80.
32. Gragoudas ES, **Egan KM**. Management of choroidal and ciliary body melanomas. *Semin Ophthalmol* 1993; 8:234-240.
33. Young L, **Egan KM**, Walsh SW, Gragoudas ES. Familial uveal melanoma. *Am J Ophthalmol* 1994; 117:516-20.
34. Shokravi MK, Marcus DM, Alroy J, **Egan KM**, Saornil MA, Albert DM. Vitamin D inhibits angiogenesis in transgenic murine retinoblastoma. *Invest Ophthalmol Vis Sci* 1995; 36:83-7.
35. Gragoudas ES, **Egan KM**, Walsh SM, Regan S, Munzenrider JE, Taratuta V. Lens changes after proton beam irradiation for uveal melanoma. *Am J Ophthalmol* 1995; 119:157-64.
36. Friedman E, Krupsky S, Lane AM, Oak SS, Friedman ES, **Egan KM**, Gragoudas ES. Ocular blood flow velocity in age-related macular degeneration. *Ophthalmology* 1995; 102:640-6.
37. Giovannucci E, **Egan KM**, Hunter DJ, et al. Aspirin use and the risk for colorectal cancer and adenoma in the Nurses' Health Study. *New Engl J Med* 1995; 333:609-14.
38. **Egan KM**, Stampfer M, Giovannucci E, Rosner B, Colditz GA. A prospective study of regular aspirin use and the risk of breast cancer. *J Natl Cancer Inst* 1996; 88:988-93.
39. **Egan KM**, Newcomb PM, Longnecker MP, Dietz AT, Baron JA, Trichopoulos D, Stampfer MJ, Willett WC. Jewish religion and risk of breast cancer. *Lancet* 1996; 347:1645-4.
40. Wang X, **Egan KM**, Gragoudas ES, Kelsey KT. Constitutional alterations on chromosome 9 in patients with uveal melanoma. *Melanoma Research* 1996; 6:405-10.
41. Katsouyanni K, Signorello LB, Laggiou P, **Egan KM**, Trichopoulos D. Evidence that adult life risk factors influence the expression of familial propensity to breast cancer. *Epidemiology* 1997; 8:592-95.
42. Lane AM, **Egan KM**, Yang J, Saornil MA, Alroy J, Albert D, Gragoudas ES. An evaluation of tumor vascularity as a prognostic indicator in uveal melanoma. *Melanoma Research* 1997; 7:237-242.
43. **Egan KM**, Giovannucci E, Titus-Ernstoff L, Newcomb P, Stampfer M. Middle-aged mothers live longer [letter]. *Nature* 1997; 389:922.
44. Gragoudas ES, **Egan KM**. Metastatic risk for distinct patterns of post irradiation local recurrence of posterior uveal melanoma [discussion]. *Ophthalmology* 1997; 104:1792-1793.

45. **Egan KM**, Ryan L, Gragoudas ES. Survival implications of enucleation after definitive radiotherapy for choroidal melanoma: An example of regression on time-dependent covariates. *Arch Ophthalmol* 1998; 116: 366-370.
46. **Egan KM**, Stampfer MJ, Rosner BA, Trichopoulos D, Newcomb PA, Trentham-Dietz A, Longnecker MP, Mittendorf R, Greenberg ER, Willett WC. Risk factors for breast cancer in women with a family history of breast cancer. *Cancer Epidemiol Biomarkers Prev* 1998; 7: 359-364.
47. Titus-Ernstoff L, **Egan KM**, Newcomb PA, Baron JA, Stampfer M, Greenberg ER, Cole BF, Ding J, Willett WC, Trichopoulos D. Exposure to breast milk in infancy and breast cancer risk in postmenopausal women. *J Natl Cancer Inst* 1998; 90: 921-924.
48. **Egan KM**, Newcomb PA, Titus-Ernstoff L, Trentham-Dietz A, Baron JA, Willett WC, Stampfer MJ, Trichopolous D. The relation of breast size to breast cancer risk in postmenopausal women. *Cancer Causes & Control* 1999; 10: 115-118.
49. Regan S, Judge H, Gragoudas ES, **Egan KM**. Iris color as a prognostic indicator in intraocular melanoma. *Arch Ophthalmol* 1999; 117: 811-814.
50. Newcomb PA, **Egan KM**, Titus-Ernstoff L, Trentham-Dietz A, Greenberg ER, Baron J, Willett WC, Stampfer MJ. Lactation in relation to postmenopausal breast cancer. *Am J Epidemiol* 1999; 150: 174-182.
51. **Egan KM**, Quinn JL, Gragoudas ES. History of childbearing confers a survival advantage in choroidal melanoma. *Arch Ophthalmol* 1999; 117: 939-942.
52. Serova-Sinilnikova O, **Egan KM**, Quinn JL, Boutrand L, Lenoir G, Stoppa-Lyonnet D, Desjardins L, Levy C, Goldgar D, and Gragoudas ES. Germline BRCA2 sequence variants in patients with ocular melanoma. *Int J Cancer* 1999; 82: 325-328.
53. Gragoudas ES, Li W, Lane AM, Munzenrider J, **Egan KM**. Risk factors for radiation maculopathy and papillopathy after intraocular irradiation. *Ophthalmol* 1999; 106: 157-177.
54. Titus-Ernstoff L, Newcomb PA, **Egan KM**, Baron JA, Greenberg ER, Willett WC, Stampfer MJ. Left-handedness in relation to breast cancer risk. *Epidemiology* 2000; 11:181-184.
55. Gragoudas ES, Lane AM, Regan S, Judge HE, Munzenrider JE, Seddon JM, **Egan KM**. A randomized controlled trial of varying radiation doses in the treatment of choroidal melanoma. *Arch Ophthalmol* 2000; 118:773-778.
56. Li W, Gragoudas ES, **Egan KM**. Metastatic melanoma death by anatomic site after proton beam irradiation for uveal melanoma. *Arch Ophthalmol* 2000; 118:1066-70.
57. Trentham-Dietz A, Newcomb PA, **Egan KM**, Titus-Ernstoff L, Baron JA, Storer BE, Stampfer M, Willett WC. Weight change and risk of postmenopausal breast cancer. *Cancer Causes & Control* 2000; 11:533-542.
58. Li W, Judge H, Gragoudas ES, Seddon JM, **Egan KM**. Patterns of tumor initiation in choroidal melanoma. *Cancer Research* 2000; 60:3757-3760.
59. Newcomb PA, Trentham-Dietz A, **Egan KM**, Titus-Ernstoff L, Baron JA, Willett WC, Stampfer M. Fracture history and risk of breast and endometrial cancer. *Am J Epidemiol* 2001; 153:1071-1078.
60. Garcia-Closas M, **Egan KM**, Abruzzo J, Newcomb P, Titus-Ernstoff L, Franklin T, Bender P, Beck J, LeMarchand L, Alavanja M, Hayes R, Rutter J, Buetow K, Brinton L, Rothman N. Collection of genomic DNA in epidemiologic studies by buccal cytobrush and mouthwash. *Cancer Epidemiol Biomarkers Prev* 2001; 10: 687-96.
61. Regan S, Gragoudas ES, **Egan KM**. Color doppler imaging of untreated and irradiated choroidal melanoma. *European J Ophthalmol* 2001; 11:150-5.

62. McElroy JA, Newcomb PA, Remington PL, **Egan KM**, Titus-Ernstoff L, Trentham-Dietz A, Hampton J, Baron JA, Stampfer, MJ, Willett WC. Electric blanket or mattress cover use and breast cancer incidence in women 50-79 years of age. *Epidemiology* 2001; 12:613-7.
63. Baron J, Weiderpass XE, Newcomb PA, Stampfer M, Titus-Ernstoff L, **Egan KM**, Greenberg ER. Metabolic disorders and breast cancer risk. *Cancer Causes&Control* 2001; 12:875-880.
64. Bertone E, Hankinson S, Newcomb P, Rosner B, Willett W, Stampfer M, **Egan KM**. A population-based case-control study of carotenoid and vitamin A intake and ovarian cancer (United States). *Cancer Causes &Control* 2001; 12: 83-90.
65. **Egan KM**, Stampfer MJ, Hunter D, Hankinson S, Rosner BA, Holmes M, Willett WC, Colditz GA. Active and passive smoking in breast cancer: prospective results from the Nurses' Health Study. *Epidemiology* 2002; 13:138-45.
66. Titus-Ernstoff L, **Egan KM**, Newcomb PA, Ding J, Trentham-Dietz A, Baron JA, Stampfer, MJ, Trichopoulos D, Willett WC. Early life factors in relation to breast cancer risk in postmenopausal women. *Cancer Epidemiol Biomarkers Prev* 2002; 11: 207-10.
67. Bertone E, Newcomb P, Willett W, Stampfer MJ, **Egan KM**. Recreational physical activity and ovarian cancer in a population-based case-control study. *Int J Cancer* 2002; 99:431-436.
68. Newcomb PA, Titus-Ernstoff L, **Egan KM**, Trentham-Dietz A, Baron J, Storer BE, Willett WC, Stampfer MJ. Postmenopausal estrogen and progestin use in relation to breast cancer risk. *Cancer Epidemiol Biomarkers Prev* 2002 11:593-600.
69. Gragoudas ES, Lane AM, Munzenrider J, **Egan KM**, Li W. Long-term risk of local failure after proton therapy for choroidal/ciliary body melanoma. *Trans Am Ophthalmol Soc* 2002; 100:43-8; discussion 48-9.
70. Gragoudas E, Li W, Goitein M, Lane AM, Munzenrider JE, **Egan KM**. Evidence-based estimates of outcome in patients irradiated for intraocular melanoma. *Arch Ophthalmol* 2002 Dec; 120(12):1665-71.
71. Newcomb PA, Kim H, Trentham-Dietz A, Farin F, Hunter D, **Egan KM**. Vitamin D receptor polymorphism and breast cancer risk. *Cancer Epidemiol Biomarkers Prev* 2002 Nov; 11(11): 1503-4.
72. **Egan KM**, Newcomb PA, Titus-Ernstoff L, Trentham-Dietz A, Mignone LI, Farin F, Hunter DJ. Association of *NAT2* and smoking in relation to breast cancer incidence in a population-based case-control study. *Cancer Causes Control* 2003 14(1):43-51.
73. **Egan KM**, Newcomb PA, Titus-Ernstoff L, Trentham-Dietz A, Mignone LI, Farin F, Hunter DJ. Association of *NAT2* and smoking in relation to breast cancer incidence in a population-based case-control study. *Cancer Causes Control* 2003 14(1):43-51.
74. Fung TT, Spiegelman D, **Egan KM**, Giovannucci E, Hunter DJ, Willett WC. Vitamin and carotenoid intake and risk of squamous cell carcinoma of the skin. *Int J Cancer* 2003 Jan 1; 103(1): 110-5.
75. Leong NM, Mignone LI, Newcomb PA, Titus-Ernstoff L, Baron JA, Trentham-Dietz A, Stampfer MJ, Willett WC, **Egan KM**. Early life risk factors in cancer: the relation of birth weight to adult obesity. *Int J Cancer* 2003 Mar 1; 103(6):789-91.
76. Li W, Gragoudas ES, **Egan KM**. Tumor basal area and metastatic death after proton beam irradiation for choroidal melanoma. *Arch Ophthalmol* 2003 Jan; 121(1): 68-72.
77. Arroyo JG, Postel EA, Stone T, McCuen BW, **Egan KM**. A matched study of primary scleral buckle placement during repair of posterior segment open globe injuries. *Br J Ophthalmol* 2003 Jan; 87(1):75-8.

78. Kang JH, Spiegelman D, Pasquale L, **Egan KM**, Willett WC, Hankinson S. A prospective study of antioxidant intake and primary open-angle glaucoma. *Am J Epidemiol* 2003 Aug 15; 158(4):337-46.
79. **Egan KM**, Thompson PA, Titus-Ernstoff L, Moore JH, Ambrosone CB. *MnSOD* polymorphism and breast cancer in a population-based case-control study. *Cancer Lett* 2003 Sep 10; 199(1):27-33.
80. Kang JH, Pasquale LR, Rosner BA, Willett WC, **Egan KM**, Faberowski N, Hankinson SE. Prospective study of cigarette smoking and the risk of primary open-angle glaucoma. *Arch Ophthalmol* 2003 Dec; 121(12):1762-8.
81. **Egan KM**, Cai Q, Shu X-O, Jin F, Zhu T-L, Dai Q, Gao Y-T, Zheng W. Genetic polymorphisms in *GSTM1*, *GSTP1* and *GSTT1* and the risk for breast cancer: Results from the Shanghai breast cancer study and meta-analysis. *Cancer Epidemiol Biomarkers Prev* 2004 13:197-204.
82. **Egan KM**, Newcomb PA, Ambrosone CB, Trentham-Dietz A, Titus-Ernstoff L, Hampton JM, Kimura M, Nagase H. *STK15* polymorphism and breast cancer risk in a population-based case-control study. *Carcinogenesis* 2004 25:2149-53.
83. Marucci L, Lane AM, Li W, **Egan KM**, Gragoudas ES, Adams JA, Collier JM, Munzenrider JE. Conservation treatment of the eye: conformal proton reirradiation for recurrent uveal melanoma. *Int J Radiat Oncol Biol Phys* 2006 Mar 15; 64(4):1018-22. Epub 2006 Jan 10.
84. García-Closas M, **Egan KM**, Newcomb PA, Brinton L, Titus-Ernstoff L, Chanock S, Lissowska J, Peplonska B, Welch R, Trentham-Dietz A, Struewing JP. Polymorphisms in DNA double strand break repair genes and risk of breast cancer in two population-based studies in the USA and Poland. *Hum Genet* 2006 May; 119(4):376-88. Epub 2006 Feb 17.
85. Long J-R, **Egan KM**, Shu X-O, Cai Q, Dunning L, Cai H, Dai Q, Gao Y-T, Holtzman J, Zheng W. Population-based case-control study of *AhR* and *CYP1A2* polymorphisms and breast cancer risk. *Pharmacogenet Genomics* 2006 Apr; 16(4):237-43.
86. Peterson NB, Trentham-Dietz A, Newcomb PA, Gebretsadik T, Hampton JM, Stampfer MJ, Willett WC, **Egan KM**. Relation of body size to ovarian cancer risk in a population-based case-control study. *Cancer Causes Control* 2006 May; 17(4):459-67.
87. Zhang Y, Newcomb PA, **Egan KM**, Titus-Ernstoff L, Chanock S, Welch R, Brinton L, Lissowska J, Szeszenia-Dąbrowska N, Zatonski W, García-Closas M. Genetic polymorphisms in base excision repair pathway genes and risk of breast cancer. *Cancer Epidemiol Biomarkers Prev* 2006 Feb; 15(2):353-8.
88. Peterson NB, Newcomb PA, Trentham-Dietz A, Chen Z, Hampton JM, Stampfer MJ, Willett WC, **Egan KM**. Alcohol consumption and ovarian cancer risk in a population-based case-control study. *Int J Cancer* 2006 Nov 15; 119(10):2423-7.
89. McElroy JA, Newcomb PA, Titus-Ernstoff L, Trentham-Dietz A, Hampton JM, **Egan KM**. Duration of sleep and breast cancer risk in a large population-based case-control study. *Journal of Sleep Research* 2006 Sep; 15(3):241-9.
90. Yatsui Y, Trentham-Dietz A, **Egan KM**, Newcomb P. Familial risk estimates for use in epidemiologic studies. *Am J Epidem* 2006 Oct 1; 164 (7):697-705.
91. Nichols HB, Trentham-Dietz A, Hampton JM, Titus-Ernstoff L, **Egan KM**, Willett W, Newcomb PA. From menarche to menopause: Trends among US women born 1912-1969. *Am J Epidemiol* 2006 Nov 15; 164(10):1003-11.
92. Committee Authorship. Breast Cancer Association Consortium. Commonly studied SNPs and breast cancer: results from 10,000 – 32,000 cases and controls from the Breast Cancer Association Consortium. *J Natl Cancer Inst* 2006 Oct 4; 98(19):1382-96.
93. McElroy JA, **Egan KM**, Titus-Ernstoff L, Anderson HA, Trentham-Dietz A, Hampton JM, Newcomb PA. Occupational exposure to electromagnetic fields (EMF) and breast cancer risk in a

- large population-based case-control study in the United States. *Journal of Occupational and Environmental Medicine* 2007 Mar; 49(3):266-74.
94. Sprague BL, Trentham-Dietz A, Newcomb PA, Titus-Ernstoff L, **Egan KM**. Lifetime recreational and occupational physical activity and risk of invasive and *in situ* breast cancer. *Cancer Epidemiol Biomarkers Prev* 2007 16:236-43.
95. Gaudet MM, **Egan KM**, Lissowska J, Newcomb PA, Brinton LA, Titus-Ernstoff L, Yeager M, Chanock S, Welch R, Peplonska B, Trentham-Dietz A, Garcia-Closas M. Genetic variation of tumor necrosis factor-alpha and lymphotoxin-alpha (*TNF-LTA*) and breast cancer risk. *Human Genetics* 2007 May; 121(3-4):483-90.
96. Moore LE, Bergen AW, Haque KA, Qi Y, Castle P, Chanock SJ, **Egan KM**, Newcomb P, Titus-Ernstoff L, Alguacil J, Rothman N, Garcia-Closas M. Whole genome amplification of buccal cytobrush DNA collected for molecular epidemiology studies. *Biomarkers* 2007 May-Jun; 12(3):303-12.
97. Sprague BL, Trentham-Dietz A, Garcia-Closas M, Newcomb PA, Titus-Ernstoff L, Hampton JM, Chanock SJ, Haines JL, **Egan KM**. Genetic variation in *TP53* and risk of breast cancer in a population-based case-control study. *Carcinogenesis* 2007 Aug; 28(8):1680-6.
98. Trentham-Dietz A, Nichols HB, **Egan KM**, Titus-Ernstoff L, Hampton JM, Newcomb PA. Cigarette smoking and risk of breast carcinoma *in situ*. *Epidemiology* 2007 Sep; 18(5):629-38.
99. Liang X, Trentham-Dietz A, Titus-Ernstoff L, Newcomb PA, Welch RA, Hutchinson AA, Hampton JM, Sutcliffe CB, Haines JL, **Egan KM**. Whole-genome amplification of oral rinse self-collected DNA in a population-based case-control study of breast cancer. *Cancer Epidemiol Biomarkers Prev* 2007 Aug; 16(8):1610-4.
100. Nichols HB, Trentham-Dietz A, **Egan KM**, Titus-Ernstoff L, Hampton JM, Newcomb PA. Oral contraceptive use and risk of breast carcinoma *in situ*. *Cancer Epidemiol Biomarkers Prev* 2007 Nov; 16(11):2262-8.
101. Pocobelli G, Newcomb PA, Trentham-Dietz A, Titus-Ernstoff L, Hampton JM, **Egan KM**. Statin use and risk of breast cancer. *Cancer* 2008 Jan 1; 112(1):27-33.
102. **Egan KM**, Signorello L, Munro HM, Hargreaves MK, Hollis B, Blot WJ. Vitamin D insufficiency among African Americans in the Southern United States: Implications for cancer disparity. *Cancer Causes & Control* 2008 Jun; 19(5):527-35.
103. Wernli KJ, Newcomb PA, Hampton JM, Trentham-Dietz A, **Egan KM**. Hormone therapy and ovarian cancer: incidence and survival. *Cancer Causes Control* 2008 Aug; 19(6):605-13.
104. Holick CN, Newcomb PA, Trentham-Dietz A, Titus-Ernstoff L, Bersch AJ, Stampfer MJ, Baron JA, **Egan KM**, Willett WC. Physical activity and survival after diagnosis of invasive breast cancer. *Cancer Epidemiol Biomarkers Prev* 2008 Feb; 17(2):379-86.
105. Newcomb PA, **Egan KM**, Trentham-Dietz A, Titus-Ernstoff L, Baron JA, Hampton JM, Stampfer MJ, Willett WC. Prediagnostic use of hormone therapy and mortality after breast cancer. *Cancer Epidemiol Biomarkers Prev* 2008 Apr; 17(4):864-71.
106. Wernli KJ, Newcomb PA, Hampton JM, Trentham-Dietz A, **Egan KM**. Inverse association of NSAID use and ovarian cancer in relation to oral contraceptive use and parity. *Br J Cancer* 2008 3:1781-3.
107. Fair AM, Wujcik D, Lin, J-M, Grau A, **Egan KM**, Zheng W. Timing is everything: methodological issues locating and recruiting medically underserved women for abnormal mammography follow-up research. *Contemp Clin Trials* 2008 Jul; 29(4):537-46.
108. Cai H, Shu X-O, **Egan KM**, Cai Q, Dunning L, Cai H, Dai Q, Gao Y-T, Holtzman J, Zheng W. Association of genetic polymorphisms in *CYP19A1* and blood levels of sex hormones among postmenopausal Chinese women. *Pharmacogenet Genomics* 2008 Aug; 18(8):657-664.

109. Sprague BL, Trentham-Dietz A, **Egan KM**, Titus-Ernstoff L, Hampton J, Newcomb PA. Population attributable risk for breast cancer among postmenopausal women. *Am J Epidemiol* 2008 Jun 13. [Epub ahead of print]
110. Peterson N, Huang Y, Newcomb PA, Titus-Ernstoff L, Trentham-Dietz A, Anic G, **Egan KM**. Evaluation of childbearing recency and modifiers of premenopausal breast cancer risk. *Cancer Epidemiol Biomarkers Prev* 2008; 17 3284-3287.
111. Jennifer Permeth-Wey, **Egan KM**. Family history is a significant risk factor for pancreatic cancer: Results from a systematic review and meta-analysis. *Fam Cancer* 2008 Sep 2. [Epub ahead of print]
112. Dos Santos Silva I, De Stavola B, McCormack V, Collaborative Group on Pre-Natal Risk Factors and Subsequent Risk of Breast Cancer (2008) Birth size and breast cancer risk: Re-analysis of individual participant data from 32 studies. *PLoS Med* 5(9): e193. doi: 10. 371/journal.pmed.0050193
113. Kumar N, Titus-Ernstoff L, Newcomb PA, Trentham-Dietz A, Anic G, **Egan KM**. Tea consumption and risk of breast cancer. *Cancer Epidemiol Biomarkers Prev* 2009 Jan; 18(1):341-5.
114. Mignone LI, Giovannucci E, Newcomb PA, Titus-Ernstoff L, Trentham-Dietz A, Hampton JM, Orav EJ, Willett WC, **Egan KM**. Meat consumption, heterocyclic amines, NAT2, and the risk of breast cancer. *Nutr Cancer* 2009; 61(1):36-46.
115. Newcomb PA, Nichols HB, Beasley J, **Egan KM**, Titus-Ernstoff L, Hampton JM, Trentham-Dietz A. Red and white wine consumption and breast cancer risk. *Cancer Epidemiol Biomarkers Prev* (in press).
116. Huang Y, Trentham-Dietz A, Garcia-Closas M, Newcomb PA, Titus-Ernstoff L, Hampton JM, Chanock SJ, Haines JL, **Egan KM**. Association of *CYP1B1* haplotypes and breast cancer risk in Caucasian women. *Cancer Epidemiol Biomarkers Prev* (in press).
117. Fair AM, Wujcik D, Lin A, Grau A, Wilson V, Champion V, Zheng W, **Egan KM**. Obesity, reproductive factors and follow-up of abnormal screening mammography in minority and medically underserved women. *Journal of Women's Health* (in press).
118. Mignone LI, Giovannucci EL, Newcomb PA, Titus-Ernstoff L, Trentham-Dietz A, Hampton JM, Willett WC, **Egan KM**. Dietary carotenoids and the risk of invasive breast cancer. *International J Cancer* (in press).
119. Wise LA, Titus-Ernstoff L, Newcomb PA, Trentham-Dietz A, Trichopoulos D, Hampton JM, **Egan KM**. Exposure to breast milk in infancy and risk of breast cancer. *Cancer Causes & Control* (in press).

Invited Publications

1. **Egan KM**. Proton beam irradiation: Conservative treatment of uveal melanomas. *New Engl J Optom* 1987; 49: 8-10.
2. **Egan KM**, Seddon J, Glynn R, Gragoudas E, Albert D. Epidemiologic aspects of uveal melanoma. *Surv Ophthalmol* 1988; 32: 239-251.
3. **Egan KM**, Giovannucci E. Dietary mutagens and the risk of breast cancer [Guest Editorial]. *J Natl Cancer Inst* 1998; 90: 1687-1689.
4. Gragoudas ES, **Egan KM**. Uveal Melanoma: A rare malignancy [Guest Editorial]. *Ophthalmology* 2000; 107:1441-2.
5. **Egan KM**, Sosman J, Blot WJ. Sunlight and a reduced risk of cancer: is the real story vitamin D? [Editorial] *J Natl CA Inst* 2005; 97: 161-163.
6. **Egan KM**. Commentary: Sunlight, vitamin D, and the cancer connection revisited. *Int J Epidemiol* 2006 Apr; 35(2):227-30.

7. **Egan KM**, Sosman J, Blot WJ. Sunlight and a reduced risk of cancer: is the real story vitamin D? [Response] J Natl Cancer Inst 2005 Aug 2; 97(15):1161-2.
8. Newcomb P, **Egan KM**. Dairy food and ovarian cancer risk. Lancet. 2006 Mar 11; 367(9513):797-9.
9. **Egan KM**. Commentary: Sunlight, vitamin D, and the cancer connection revisited. Int J Epidemiol 2006 Apr; 35(2):227-30.
10. **Egan KM**. Vitamin D and Melanoma. Annals Epidemiology 2009 (in press).

Book Chapters

1. Seddon J, **Egan KM**, Gragoudas E, Glynn R. Epidemiology of uveal melanoma. In: Ryan's Diseases and Surgery of the Retina and Vitreous, Vol. I, Schachat AP, ed. Tumors of the Retina, Choroid and Vitreous. 2nd ed. St Louis: S.V. Mosby, 1994.
2. Seddon J, **Egan KM**, Gragoudas E. Uveal melanoma prognosis. In: Ryan's Diseases and Surgery of the Retina and Vitreous, Vol. I, Schachat AP, ed. Tumors of the Retina, Choroid and Vitreous. 2nd ed. St. Louis: C.V. Mosby, 1994.
3. Gragoudas E, Seddon J, **Egan KM**. Charged particle irradiation of uveal melanomas. In: Ryan's Diseases and Surgery of the Retina and Vitreous, Vol. I, Schachat AP, ed. Tumors of the Retina, Choroid and Vitreous. 2nd ed. St. Louis: C.V. Mosby, 1994.
4. **Egan KM**, Seddon JM. Age-Related Macular Degeneration: Epidemiology. In: Principles and Practice of Ophthalmology. Basic Sciences. Albert DM and Jakobiec FA, eds. Philadelphia: WB Saunders Company, 1994.
5. Seddon JM, **Egan KM**. Application of Epidemiologic Methods to the Study of Eye Disease: Uveal Melanoma. In: Principles and Practice of Ophthalmology. Basic Sciences. Albert DM and Jakobiec FA, eds. Philadelphia: WB Saunders Company, 1994.
6. Gragoudas ES, Char D, **Egan KM**. Charged particle irradiation of uveal melanomas. In: Principles and Practice of Ophthalmology. Albert DM and Jakobiec FA, eds. Philadelphia: WB Saunders, 2000.

Scientific Abstracts/Poster Presentations/Plenary Presentations:

1. **Egan KM**, Seddon J, Gragoudas E, Hsieh C-c, Greer J, Osuna F. Tumor height regression of uveal melanomas treated by proton beam irradiation. Invest Ophthalmol Vis Sci 27 (ARVO Suppl); 312, 1986.
2. **Egan KM**, Seddon JM, Gragoudas ES, Polivogianis L, Glynn RJ. A computerized database for patients with uveal melanoma. Second International Meeting in Diagnosis and Treatment of Intraocular Tumors; Nyon, Switzerland, November 23-27, 1987.
3. **Egan KM**, Seddon J, Gragoudas E, Glynn R, Finn S, Greer J, Osuna F. Uveal Melanoma in New England: Profile of cases diagnosed in 1984. Invest Ophthalmol Visual Sci 28 (ARVO Suppl); 144, 1987.
4. **Egan KM**, Seddon JM, Lischko AM, Glynn RJ, and Gragoudas ES. Evaluation of hormonal risk factors for uveal melanoma among women. Invest Ophthalmol Visual Sci 30 (ARVO Suppl); 109, 1989.
5. **Egan KM**, Saornil MA, Gragoudas ES, Young J, Walsh SM, Seddon JM, and Albert DM. Tumor vascularity and prognosis in uveal melanoma. American Academy of Ophthalmology meeting, Anaheim, Oct 13-17, 1991.
6. **Egan KM**. Incidence of choroidal melanoma in New England: 1984 to 1989. International Symposium on Ocular Tumors. April 29 to May 1, 1992. New York, New York.

7. **Egan KM**, Wang X, Gragoudas ES, Kelsey KT. Constitutional alterations on chromosome 9 in patients with uveal melanoma. *Invest Ophthalmol Visual Sci* 36 (ARVO Suppl); s770, 1995.
8. **Egan KM**, Gragoudas ES. Impact of enucleation on patient survival following proton irradiation for choroidal melanoma. *Invest Ophthalmol Visual Sci* 37 (ARVO Suppl); s1134, 1996.
9. **Egan KM**, Newcomb P, Willett W, Stampfer M. Physical activity and invasive epithelial ovarian cancer. Society for Epidemiologic Research meeting, Boston, June 1996.
10. **Egan KM**, Mukai S, Gragoudas ES. The genetic epidemiology of intraocular melanoma. International Symposium on Ocular Tumors, Jerusalem, April 6-10, 1997.
11. **Egan KM**, Glynn RJ, Gragoudas ES. Time-varying prognostic factors for death from metastasis in choroidal melanoma. International Symposium on Ocular Tumors, Jerusalem, April 6-10, 1997.
12. **Egan KM**, Giovannucci E, Lane AM, Gragoudas ES. A prospective study of diet as a prognostic factor in choroidal melanoma. *Invest Ophthalmol Visual Sci* 39 (ARVO Suppl); s464, 1998.
13. **Egan KM**, Giovannucci E, Gragoudas ES, Pollack M. Role of serum insulin-like growth factor (IGF)-I in the progression of choroidal melanoma. *Invest Ophthalmol Visual Sci* 41 (ARVO Suppl); s382, 2000.
14. **Egan KM**, Gragoudas ES. Mortality after diagnosis with indeterminate pigmented lesions of the choroid. *Invest Ophthalmol Visual Sci* 42 (ARVO Suppl); s68, 2001.
15. **Egan KM**, Lane AM, Gragoudas ES, Benichou G. Immune response to p53 in ocular melanoma. First International Melanoma Research Congress. Philadelphia, PA, June 21, 2003.
16. **Egan KM**, Cai Q, Shu X-O, Jin F, Zhu T-L, Dai Q, Gao Y-T, Zheng W. Genetic polymorphisms in *GSTM1*, *GSTP1* and *GSTT1* and the risk of breast cancer. American Association of Cancer Researchers, Washington, DC, July, 2003.
17. Malin A, Wujcik D, Grau A, Zheng W, **Egan KM**. Delayed resolution of incomplete mammograms in the public hospital setting. 3rd Annual AACR International Conference on Frontiers in Cancer Prevention Research. Seattle WA, October 2004.
18. Peterson, NB, Trentham-Dietz A, Newcomb PA, Gabretsadik, T, **Egan KM**. Body-mass index in relation to ovarian cancer risk in a population-based case-control study. *Journal Gen Intern Med*; 19 S1: 126, 2004.
19. Newcomb PA, Nichols HB, Trentham-Dietz A, Titus-Ernstoff L, Hampton JM, **Egan KM**. Wine consumption and breast cancer risk. *Am J Epidemiol* 161: S56, 2005.
20. Trentham-Dietz A, Newcomb P, Titus-Ernstoff L, **Egan KM**. Weight gain and risk of carcinoma in situ of the breast. *Am J Epidemiol* 163(11):S98, 2006.
21. Pocobelli G, Newcomb P, Trentham-Dietz A, Titus-Ernstoff L, Hampton J, **Egan KM**. Statin use and the risk of breast cancer. *Am J Epidemiol* 163(11):S37, 2006.
22. **Egan KM**, Trentham-Dietz A, Chanock S, Newcomb P, Welch R, Titus-Ernstoff L, Hampton J, Haines J, Garcia-Closas M. Genetic variation in *CYP1A1*, *CYP1A2*, and *CYP1B1* and risk of invasive breast cancer in a US population-based case-control study. American Association of Cancer Researchers, Washington, DC, April 2006.
23. Liang X, Newcomb PA, Titus-Ernstoff L, Trentham-Dietz A, Garcia-Closas M, Welch R, Hutchinson A, Hampton JM, Ballard-Sutcliffe C, Haines JL, **Egan KM**. Whole genome amplification of oral rinse self-collected DNA in a population-based case-control study of breast cancer. American Association of Cancer Researchers, Washington, DC, April 2006.
24. Trentham-Dietz A, Garcia-Closas M, Sprague BL, Newcomb PA, Titus-Ernstoff L, Hampton JM, Chanock S, **Egan KM**. Genetic variation in *TP53* and risk of breast cancer in a population-based case-control study. American Association of Cancer Researchers, Washington, DC, April 2006.

25. Trentham-Dietz A, PA Newcomb PA, Titus-Ernstoff L, **Egan KM**. Weight gain and risk of carcinoma *in situ* of the breast. Society for Epidemiologic Research, Seattle, WA, June 2006.
26. Lane AM, Gragoudas ES, **Egan KM**. The role of sunlight in progression of ocular melanoma. Invest Ophthalmol Visual Sci 2007; 48: ARVO E-Abstract 55.
27. Trentham-Dietz A, Nichols H, Newcomb PA, Titus-Ernstoff L, Remington P, Baron JA, Greenberg ER, Stampfer M, Willett W, **Egan KM**. Risk factors for inflammatory breast cancer. American Society of Preventive Oncology, Houston TX, March 2007.
28. Wernli KJ, Newcomb PA, Trentham-Dietz A, Hampton JM, Wong EY, **Egan KM**. Duration and type of postmenopausal hormone use and ovarian cancer. Cancer Epidemiol Biomarkers Prev 16(2):361, 2007.
29. Nichols HB, Trentham-Dietz A, Newcomb PA, Titus-Ernstoff L, **Egan KM**. Post-diagnosis weight change, body mass index, and breast cancer survival. American Association of Cancer Research Frontiers Annual Meeting. December 5-8, 2007, Philadelphia, PA.
30. Crosby SM, Edgeworth ML, **Egan KM**, Thompson RC. Incidence, radiographic, and clinicopathological features of atypical meningioma: A 7-year experience. Poster Presentation for the Society of Neuro-Oncology, Dallas, TX, November 2007
31. Wernli KJ, Newcomb PA, Hampton JM, **Egan KM**, Trentham-Dietz A. Parity modifies the relationship between NSAIDs and ovarian cancer. Frontiers in Cancer Prevention Meeting at AACR, San Diego, CA, April 2008.
32. Park, JY, **Egan, KM**, Huang, Y, Lewis, JM, Messina, J, Sondak, V, Zheng, W and Sellers, TA. (2008). Genetic variation in lymphangiogenesis in relation to lymph node metastasis in patients with cutaneous melanoma. Annual Meeting of American Association for Cancer Research. April 12-16, 2008. San Diego, CA.
33. Lane AM, Cubitt CL, Yocum JD, Chaglassian A, Gragoudas ES, **Egan KM**. Serum concentrations of interleukin-6 and metastasis from uveal melanoma. Invest Ophthalmol Visual Sci 2008; 49: ARVO E-Abstract 4793.
34. Anic GM, Kumar N, Newcomb PA, Titus-Ernstoff L, Trentham-Dietz A, **Egan KM**. Tea consumption and the risk of breast cancer. Moffitt Research Institute Scientific Retreat. Tampa, FL, February 22, 2008.
35. Newcomb PA, Trentham-Dietz A, Hampton JM, Titus-Ernstoff L, **Egan KM**. Changing birth patterns are associated with increased lobular breast cancer risk. Association for Preventive Oncology. 2009

Invited Seminars

1. Resident's Lecture. Department of Ophthalmology, University of Valladolid, Valladolid, Spain. 1994 "The Biology and Epidemiology of Intraocular Melanomas."
2. Research Subcommittee of the MA Department of Public Health. Boston, MA. 1996 "Risk Factors for Breast Cancer."
3. Association for Research in Vision and Ophthalmology Annual Meeting. Sarasota, FL. 1996 Moderator: Clinical & Epidemiologic Research, Anatomy & Pathology: Choroidal Melanoma.
4. 50th Annual Meeting of the Tomato Growers Association. Sacramento, CA. 1997 "Carotenoids in Cancer and Eye Disease Prevention."
5. Center for Human Genetics. Human Genetics Seminar Series. Boston University School of Medicine. Boston, MA. 1997 "Family History Interactions in Breast Cancer." American Cancer Society, Framingham, MA. Epidemiologic End-Uses of Cancer Registry Data.
6. Massachusetts Department of Public Health: Conference on Cancer in Women. Boston, MA. 1997 "Physical Activity and Diet in Cancer."

7. Association for Research in Vision and Ophthalmology Annual Meeting. Ft.. Lauderdale, FL. 1998 Moderator: Clinical & Epidemiologic Research, Retina and AMD and Choroidal Melanoma: Epidemiology.
8. Conference on Molecular Basis for the Prevention of Colon, Breast, and Other Cancers by Aspirin and Other NSAID's. National Institute of Environmental Health Sciences. Research Triangle Park, North Carolina. 1998 "Aspirin Use and Breast Cancer".
9. International Society for Eye Research. Paris, France. 1998 "A Breast Cancer Gene in Ocular Melanoma?"
10. American Chemical Society. Washington, DC. 2000 "Is Active or Passive Smoking Linked to Breast Cancer?"
11. Association for Research in Vision and Ophthalmology Annual Meeting. Ft. Lauderdale, FL. 2001 "BRCA2 and Uveal Melanoma."
12. Memorial Sloan-Kettering Cancer Center. Cancer Prevention, Control, and Population Research Seminar Series. New York, NY. 2002 "The Genetic Risk of Breast Cancer: Results from the Collaborative Breast Cancer Study"
13. Vanderbilt Divinity School. Nashville, TN. Lecture on Cancer Epidemiology in the course: "A thing that cannot and can be changed: A practical theology of cancer" (Instructor: Leonard M. Hummel)
14. Vanderbilt University Medical Center. Epidemiology Seminar Series. Nashville, TN. 2002 "MnSOD polymorphisms and Breast Cancer Incidence".
15. Vanderbilt University Medical Center. Department of Dermatology. Nashville, TN. 2003 "Epidemiology of Cutaneous Melanoma: Update and Future Horizons."
16. Vanderbilt University Medical Center. Skin Disease Research Center Core Seminar Series. Nashville, TN. 2003 "Epidemiology of Cutaneous Melanoma".
17. Vanderbilt University Medical Center. Epidemiology Seminar Series. Nashville, TN. 2003 "Immune Response to P53 in Ocular Melanoma Survival".
18. Vanderbilt University Medical Center. Epidemiology Seminar Series. Nashville, TN. 2003 "Parity and Breast Cancer Outcome".
19. Vanderbilt School of Medicine. Department of Neurosurgery. Brain Tumor Therapy. State of the Art. Nashville, TN 2004 "Epidemiology of Brain Cancer: Who is at risk?"
20. University of Alabama at Birmingham Brain Tumor Treatment and Research Program Seminar. Birmingham, AL. 2004 "Epidemiology of Glioma: Overview and New Directions.
21. Southwest Oncology Group. SWOG Myeloma Working Group. Kansas City, MS. 2004 "Molecular Predictors of Multiple Myeloma Progression".
22. Brain Tumor Center Seminar Series. Vanderbilt University. Nashville, TN. 2004 "Epidemiology of Brain Cancer".
23. 3rd International Neuro-Oncology Update. University of Memphis. Memphis, TN. 2004 "Application of the Epidemiologic Method to the Study of Primary Brain Tumors".
24. Vanderbilt-Ingram Cancer Center. Melanoma Research Conference. Nashville, TN. 2004 Epidemiology Seminar Series. Nashville, TN. "Epidemiology of Cutaneous Melanoma: Update and New Horizons".
25. Vanderbilt University Medical Center. Epidemiology Seminar Series. Nashville, TN. 2004 "STK15 Polymorphisms and Breast Cancer Incidence"
26. Kentucky Astrocytoma Research Endeavor. Innovations in Brain Tumor Care. Louisville, KY. 2005 "Genetic Epidemiology of Adult-Onset Glioma"

27. Vanderbilt University Medical Center. Epidemiology Seminar Series. Nashville, TN. 2005 “Vitamin D: A novel prognostic marker in eye melanoma?”
28. Center for Health Research. Tennessee State University. Nashville, TN. 2005 “The Vitamin D-Cancer Hypothesis”
29. Vanderbilt-Ingram Cancer Center. VICC Interprogrammatic Retreat. Nashville, TN. 2006 “Vitamin D and Cancer Disparities in the Southern Community Health Study”
30. University of Pittsburgh Cancer Institute. Brain Tumor Program Seminar Series. Pittsburgh, PA. 2006 “The epidemiology of brain cancer – new insights from molecular genetics”
31. Susan G. Komen Breast Cancer Foundation. *Many Faces: One Voice*. University of Texas Southwestern, Dallas, TX. 2006 Scientific moderator for session entitled: “Researching the genetic components of breast cancer”
32. Vanderbilt University Medical Center. Department of Medicine Grand Rounds. Nashville, TN. 2006 “The Vitamin D - Cancer Hypothesis”
33. H. Lee Moffitt Cancer Center & Research Institute. Tampa, FL. 2006 “The Vitamin D-Cancer Hypothesis - Update”
34. H. Lee Moffitt Cancer Center & Research Institute. Moffitt Scientific Retreat, Tampa, FL. 2007 “The Search for Low Penetrance Susceptibility Genes in Breast Cancer”
35. University of Florida College of Medicine. 1st Annual FL Brain Tumor Biomedical Technology Summit, Gainesville, FL. 2007 “Neuroepidemiological Studies of Brain Tumors”.
36. H. Lee Moffitt Cancer Center & Research Institute. Grand Rounds in Populations Sciences, Tampa, FL. 2008 “Reproductive Factors in Cancer Outcome with Emphasis on Breast Cancer and Melanoma”